Faridi Saavedra

Dr. Faridi Saavedra

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
JLJaneth Lozano-Mendoza
Janeth Lozano-Mendoza
FRFátima Ramírez-Montiel
Fátima Ramírez-Montiel
ÁRÁngeles Rangel-Serrano
Ángeles Rangel-Serrano
IPItzel Páramo-Pérez
Itzel Páramo-Pérez
CMClaudia L. Mendoza-Macías
Claudia L. Mendoza-Macías
FPFelipe Padilla-Vaca
Felipe Padilla-Vaca
Entamoeba histolytica virulence results from complex host–parasite interactions implicating multiple amoebic components (e.g., Gal/GalNAc lectin, cysteine proteinases, and amoebapores) and host factors (microbiota and immune response). UG10 is a strain derived from E. histolytica virulent HM-1:IMSS strain that has lost its virulence in vitro and in vivo as determined by a decrease of hemolytic, cytopathic, and cytotoxic activities, increased susceptibility to human complement, and its inability to form liver abscesses in hamsters. We compared the transcriptome of nonvirulent UG10 and its parental HM-1:IMSS strain. No differences in gene expression of the classical virulence factors were observed. Genes downregulated in the UG10 trophozoites encode for proteins that belong to small GTPases, such as Rab and AIG1. Several protein-coding genes, including iron-sulfur flavoproteins and heat shock protein 70, were also upregulated in UG10. Overexpression of the EhAIG1 gene (EHI_180390) in nonvirulent UG10 trophozoites resulted in augmented virulence in vitro and in vivo. Cocultivation of HM-1:IMSS with E. coli O55 bacteria cells reduced virulence in vitro, and the EhAIG1 gene expression was downregulated. In contrast, virulence was increased in the monoxenic strain UG10, and the EhAIG1 gene expression was upregulated. Therefore, the EhAIG1 gene (EHI_180390) represents a novel virulence determinant in E. histolytica.

10 June 2024 in Cells
Verified
Journal Article
Open access
PDF file
HMHipolito Otoniel Miranda
Hipolito Otoniel Miranda
Faridi SaavedraFaridi Saavedra
Faridi Saavedra
MGMarina Galicia-Moreno
Marina Galicia-Moreno
SAScarlet Arceo-Orozco
Scarlet Arceo-Orozco
FCFernando Caloca-Camarena
Fernando Caloca-Camarena
HMHugo Christian Monroy-Ramirez
Hugo Christian Monroy-Ramirez
Hepatocellular carcinoma (HCC) development is associated with altered modifications in DNA methylation, changing transcriptional regulation. Emerging evidence indicates that DNA methyltransferase 1 (DNMT1) plays a key role in the carcinogenesis process. This study aimed to investigate how pirfenidone (PFD) modifies this pathway and the effect generated by the association between c-Myc expression and DNMT1 activation. Rats F344 were used for HCC development using 50 mg/kg of diethylnitrosamine (DEN) and 25 mg/kg of 2-Acetylaminofluorene (2-AAF). The HCC/PFD group received simultaneous doses of 300 mg/kg of PFD. All treatments lasted 12 weeks. On the other hand, HepG2 cells were used to evaluate the effects of PFD in restoring DNA methylation in the presence of the inhibitor 5-Aza. Histopathological, biochemical, immunohistochemical, and western blot analysis were carried out and our findings showed that PFD treatment reduced the amount and size of tumors along with decreased Glipican-3, β-catenin, and c-Myc expression in nuclear fractions. Also, this treatment improved lipid metabolism by modulating PPARγ and SREBP1 signaling. Interestingly, PFD augmented DNMT1 and DNMT3a protein expression, which restores global methylation, both in our in vivo and in vitro models. In conclusion, our results suggest that PFD could slow down HCC development by controlling DNA methylation.

5 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
HMHipolito Otoniel Miranda
Hipolito Otoniel Miranda
Faridi SaavedraFaridi Saavedra
Faridi Saavedra
MGMarina Galicia-Moreno
Marina Galicia-Moreno
SAScarlet Arceo-Orozco
Scarlet Arceo-Orozco
FCFernando Caloca-Camarena
Fernando Caloca-Camarena
HMHugo Christian Monroy-Ramirez
Hugo Christian Monroy-Ramirez
Hepatocellular carcinoma (HCC) development is associated with altered modifications in DNA methylation, changing transcriptional regulation. Emerging evidence indicates that DNA methyltransferase 1 (DNMT1) plays a key role in carcinogenesis process. This study aimed to investigate how pirfenidone (PFD) modifies this pathway and the effect generated by the association between c-Myc expression and DNMT1 activation. Rats F344 were used for HCC development using 50 mg/kg of diethylnitrosamine (DEN) and 25 mg/kg of 2-aminofluorene (2-AAF). HCC/PFD group received simultaneous doses of 300 mg/kg of PFD. All treatments lasted 12 weeks. On the other hand, HepG2 cells were used to evaluate the effects of PFD in restoring DNA methylation in the presence of the inhibitor 5-Aza. Histopathological, biochemical, immunohistochemical, and western blot analysis were carried out and our findings showed that PFD treatment reduced the amount and size of tumors along with decreased Glipican-3, β-catenin, and c-Myc expression in nuclear fractions. Also, this treatment improved lipid metabolism by modulating PPARγ and SREBP1 signaling. Interestingly, PFD augmented DNMT1 and DNMT3a protein expression, which restores global methylation, both in our in vivo and in vitro models. In conclusion, our results suggest that PFD could slow down HCC development by controlling DNA methylation.

1 November 2026 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Open access
Faridi SaavedraFaridi Saavedra
Faridi Saavedra
NRNayabei Ruiz-Ramirez
Nayabei Ruiz-Ramirez
HMHugo Christian Monroy-Ramirez
Hugo Christian Monroy-Ramirez
ASAna Sandoval-Rodriguez
Ana Sandoval-Rodriguez
VRVíctor Ruiz
Víctor Ruiz
Jesús García-BañuelosJesús García-Bañuelos
Jesús García-Bañuelos
This study demonstrates that by epigenetically modifying p53 and histone H3K9 acetylation, adenoviral Sirtuin 1 (SIRT1) gene delivery reverses established pulmonary fibrosis and restores epithelial cell viability. Unlike previous techniques that relied on pharmacological activation, our results support the translational potential of SIRT1 as a therapeutic intervention for pulmonary fibrosis by establishing its overexpression as a gene-based antifibrotic strategy.